U.S. private equity firm Advent International and Dutch fund of funds investor AlpInvest have sold their holdings in oncology therapy business Nucletron for €365 million, AltAssets reports. The buyer is oncology and brain disorder treatment specialist Elekta.
Through the transaction, Elekta’s customer base of more than 5,000 will be increased by 1,000. Advent bought a minority stake in Nucletron through an investment in Delft Instruments in 2004.
Click here for the story from AltAssets.